Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Shattuck Labs, Inc.

Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers IRON STTK
Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn’s and Colitis Congress
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Announces Participation in Upcoming December Conferences
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Announces Participation in Upcoming March Conferences
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.